{"entity":{"id":"nct05222555","kind":"trial","name":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","aka":["MINDway"],"tldr":"A phase 1/2 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Corporation, active and no longer recruiting.","summary":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients is a phase 1/2 interventional study registered as NCT05222555 by Incyte Corporation, with 53 participants enrolled, started 2022-07-19 and due to reach its primary completion in 2024-07-17. Interventions recorded: Tafasitamab, Lenalidomide. Conditions listed: Diffuse Large B Cell Lymphoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05222555","url":"https://clinicaltrials.gov/study/NCT05222555"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["monoclonal-antibody","protac-degrader"],"targets":[],"drugs":["tafasitamab","lenalidomide"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05222555","phase":"1/2","setting":"A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","sponsor":"Incyte Corporation","started":"2022-07-19","startedType":"actual","yearReported":2025,"enrolled":53,"enrolledBasis":"registry","outcomes":[{"endpoint":"Number of Participants With Any Treatment-emergent Adverse Event (TEAE)","primary":true,"unit":"participants","arms":[{"name":"Tafasitamab Dose Level 1 + 25 mg Lenalidomide","n":6,"value":6,"note":"Figures from the ClinicalTrials.gov results section (first posted 2025-07-28), not from a publication"},{"name":"Tafasitamab Dose Level 2 + 25 mg Lenalidomide","n":47,"value":45}],"source":"https://clinicaltrials.gov/study/NCT05222555?tab=results"}]},"route":"/trials/nct05222555/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}]}}